This synergistic effect is particularly groundbreaking for drug-resistant tumors (e.g., MHC-I antigen-presentation-deficient tumors), where MICB, a highly conserved stress molecule, is widely expressed in different tumor types, giving cellular therapeutic oncology drugs targeting MICB antigens the potential to be “generalized”, bypassing the limitations of individualized antigens. Here, MICB is linked to neoplasm.